Residency · Residency · Family Medicine

Chronic Kidney Disease: Detection, Slowing Progression, and Referral

Overview

Chronic kidney disease affects approximately 37 million US adults, making it one of the most common conditions managed in primary care. The majority of CKD care occurs in the family physician's office, and early detection paired with aggressive intervention can meaningfully slow progression, reduce cardiovascular risk, and delay the need for renal replacement therapy.

Definition and Staging

CKD Definition

CKD is defined as abnormalities of kidney structure or function persisting for more than three months with implications for health. The diagnosis requires either a decreased GFR below 60 mL/min/1.73 m2 or markers of kidney damage such as albuminuria, hematuria, or structural abnormalities on imaging.

eGFR Calculation

The CKD-EPI 2021 equation is the current recommended method for estimating GFR and notably removes race as a variable from the calculation. The equation is based on serum creatinine, though cystatin C can be used for confirmation or in situations where creatinine is unreliable, such as patients at extremes of muscle mass or amputees. Clinicians should be aware that creatinine-based eGFR can overestimate kidney function in sarcopenic elderly patients.

GFR Staging

GFR staging runs from G1 (90 or above, normal or high, where CKD is only diagnosed if other markers of damage are present) through G2 (60 to 89, mildly decreased, also requiring other markers), G3a (45 to 59, mild-moderate decrease), G3b (30 to 44, moderate-severe decrease), G4 (15 to 29, severely decreased), to G5 (below 15, kidney failure).

Albuminuria Staging

Albuminuria is staged using the urine albumin-to-creatinine ratio (UACR) from a spot morning specimen. A1 (below 30 mg/g) is normal to mildly increased. A2 (30 to 300 mg/g, formerly called microalbuminuria) is moderately increased. A3 (above 300 mg/g, formerly macroalbuminuria) is severely increased.

KDIGO Heat Map

The KDIGO heat map combines GFR stage and albuminuria category to determine overall risk of progression, ranging from green (low risk) to red (very high risk). This color-coded grid guides both monitoring frequency and referral decisions.

Screening

Screening should target high-risk populations: patients with diabetes, hypertension, cardiovascular disease, family history of CKD, obesity, and those over 60. Annual UACR and eGFR measurement is recommended for all patients with diabetes and hypertension. The ADA recommends screening at diagnosis for type 2 diabetes and five years after diagnosis for type 1 diabetes.

Common Etiologies

Diabetic kidney disease is the most common cause of end-stage renal disease. Hypertensive nephrosclerosis is the second leading cause. Other important etiologies include glomerulonephritis (IgA nephropathy being the most common primary glomerulonephritis worldwide), polycystic kidney disease, obstructive uropathy, drug-induced injury (from NSAIDs, lithium, calcineurin inhibitors), and renovascular disease.

Slowing Progression

Blood Pressure Control

The target blood pressure for CKD with albuminuria is below 130/80 mmHg. ACE inhibitors or ARBs are first-line for CKD with albuminuria (UACR of 30 mg/g or above) because of their renoprotective effects beyond blood pressure lowering. After initiation, clinicians should expect and tolerate up to a 30% rise in creatinine, which reflects a hemodynamic effect rather than kidney injury. Creatinine and potassium should be monitored within one to two weeks of starting or adjusting the dose. ACE inhibitors and ARBs should never be combined, as the ONTARGET and VA NEPHRON-D trials demonstrated increased hyperkalemia and acute kidney injury without benefit.

SGLT2 Inhibitors

SGLT2 inhibitors have become standard of care for CKD. The DAPA-CKD trial demonstrated that dapagliflozin reduced CKD progression by 39% regardless of diabetes status, and the EMPA-KIDNEY trial showed similar benefits for empagliflozin across a broad eGFR range. These agents are now indicated for CKD with eGFR of 20 or above and UACR of 200 mg/g or higher, or for any CKD patient with diabetes. Treatment can be initiated even at eGFR as low as 20. An initial dip in eGFR is expected and hemodynamic in nature, not harmful. Benefits extend beyond kidney protection to include reduced heart failure hospitalization.

Finerenone (Non-Steroidal MRA)

Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has shown benefit in diabetic kidney disease through the FIDELIO-DKD and FIGARO-DKD trials, reducing both CKD progression and cardiovascular events. It is indicated for patients with type 2 diabetes, CKD, and albuminuria who are already on ACE inhibitor or ARB therapy. Potassium must be monitored closely, though the risk of hyperkalemia is lower than with spironolactone.

GLP-1 Receptor Agonists

The FLOW trial demonstrated that semaglutide reduced CKD progression in diabetic kidney disease, establishing an emerging role for GLP-1 receptor agonists in CKD management that extends beyond glycemic control.

Dietary and Lifestyle

Moderate protein restriction to 0.8 g/kg/day is recommended for CKD stages G3 through G5, and high-protein diets should be avoided. Sodium should be restricted to less than 2 grams per day. Smoking cessation is important because smoking accelerates CKD progression. Moderate physical activity is both safe and beneficial, and weight management supports overall kidney health.

Medication Adjustments in CKD

Medication management requires careful attention to renal dosing. Metformin is safe down to eGFR 30 but should be dose-reduced between eGFR 30 and 45 and discontinued below 30. NSAIDs should be avoided in CKD because they accelerate progression, cause hyperkalemia, and increase the risk of acute kidney injury. Gabapentin and pregabalin require dose reduction. DOAC doses must be adjusted based on agent-specific eGFR thresholds. Contrast media poses the greatest risk of acute kidney injury at eGFR below 30, and hydration is the key preventive measure. All medications should be reviewed for renal dosing adjustments at each visit.

Complications Management

Anemia

A CBC and iron studies should be checked when eGFR falls below 45. Iron stores should be replenished first (targeting ferritin above 100 and TSAT above 20%), and oral iron is often insufficient in CKD, making intravenous iron a frequent necessity. Erythropoiesis-stimulating agent therapy is typically managed by nephrology, with a hemoglobin target of 10 to 11.5 g/dL. Targeting hemoglobin above 13 g/dL increases cardiovascular events, as demonstrated in the TREAT and CHOIR trials.

Mineral and Bone Disorder (CKD-MBD)

Monitoring of calcium, phosphorus, PTH, and vitamin D should begin at CKD stage G3. Hyperphosphatemia is managed with dietary phosphorus restriction and phosphate binders such as calcium carbonate, sevelamer, or lanthanum. Secondary hyperparathyroidism should first be addressed by correcting vitamin D deficiency; persistent elevation may require calcitriol or active vitamin D analogs. DEXA scanning is unreliable for fracture prediction in advanced CKD.

Metabolic Acidosis

Serum bicarbonate below 22 mEq/L is associated with faster CKD progression and muscle wasting. Sodium bicarbonate supplementation (650 to 1300 mg three times daily) may slow progression, though monitoring for sodium and volume overload is necessary.

Hyperkalemia

Dietary potassium restriction becomes necessary in advanced CKD. Medications contributing to hyperkalemia should be reviewed, including ACE inhibitors, ARBs, MRAs, trimethoprim-sulfamethoxazole, and NSAIDs. Potassium binders such as patiromer and sodium zirconium cyclosilicate can enable continued RAAS blockade in patients who develop mild hyperkalemia.

Cardiovascular Risk

CKD is a coronary artery disease risk equivalent. Statin therapy is recommended for CKD stages G3 through G5 not on dialysis, supported by the SHARP trial. Aggressive management of blood pressure, glucose, lipids, and smoking is essential.

Nephrology Referral Criteria

Referral to nephrology is appropriate when eGFR falls below 30 (for ESRD planning and arteriovenous fistula timing), when eGFR is declining rapidly (more than 5 mL/min/year), when persistent albuminuria at the A3 level (above 300 mg/g) persists despite treatment, when hypertension is refractory, when there is persistent hematuria of unknown etiology, when hereditary kidney disease is suspected (such as polycystic kidney disease or Alport syndrome), for recurrent or extensive nephrolithiasis, or when glomerulonephritis is suspected.

Preparing for Renal Replacement Therapy

At eGFR below 20, discussions about renal replacement options should begin, including hemodialysis, peritoneal dialysis, kidney transplantation, and conservative management. Arteriovenous fistula placement should be referred at eGFR below 20 to 25 because fistulas require two to three months to mature and have significant primary failure rates. Transplant evaluation should be initiated at eGFR below 20 for pre-emptive transplant workup. Hepatitis B vaccination should be completed early, as the immune response is impaired in advanced CKD. Intravenous access in the non-dominant arm should be avoided to preserve veins for future fistula creation.

<image>The KDIGO CKD heat map showing the risk-based grid with GFR stages (G1-G5) on the vertical axis and albuminuria categories (A1-A3) on the horizontal axis. Each cell is color-coded from green (low risk) to red (very high risk), with annotations showing recommended monitoring frequency and referral thresholds for each risk category.</image>

<image>A pharmacotherapy timeline for CKD management showing when to initiate and adjust key medications as eGFR declines from 90 to 15. Include ACEi/ARB initiation for albuminuria, SGLT2i addition, finerenone for diabetic CKD, statin therapy, ESA considerations, phosphate binder introduction, and medication discontinuation thresholds (metformin at eGFR 30, NSAID avoidance). Show each drug as a horizontal bar across the eGFR range.</image>

<image>An infographic showing the three-pillar approach to slowing CKD progression: (1) RAAS blockade with ACEi/ARB, (2) SGLT2 inhibitor therapy, and (3) non-steroidal MRA (finerenone) for diabetic CKD. For each pillar, include the key trial name, magnitude of benefit, and monitoring requirements. Show these as complementary and additive therapies.</image>

Clinical Pearls

The initial eGFR dip after starting an ACE inhibitor, ARB, or SGLT2 inhibitor is hemodynamic and expected. Do not reflexively discontinue these agents unless creatinine rises more than 30% or clinically significant hyperkalemia develops. The CKD-EPI 2021 equation removed race from the eGFR calculation, which may reclassify some patients to higher CKD stages. SGLT2 inhibitors are now standard of care for CKD with albuminuria regardless of diabetes status. NSAIDs should be avoided in CKD patients, as even short courses can precipitate acute kidney injury and accelerate progression. Potassium binders can enable continued RAAS blockade in patients with mild hyperkalemia, preserving the renoprotective benefit of these agents. Early referral for AV fistula creation at eGFR below 20 to 25 is important because maturation takes months and primary failure rates are significant. CKD patients are more likely to die from cardiovascular disease than to progress to dialysis, making aggressive cardiovascular risk factor management essential. Metabolic acidosis with bicarbonate below 22 accelerates both CKD progression and muscle wasting and should be treated with oral bicarbonate.

References

• KDIGO 2024 Clinical Practice Guideline for CKD Evaluation and Management
• Heerspink HJL et al. DAPA-CKD: Dapagliflozin in CKD. NEJM. 2020
• The EMPA-KIDNEY Collaborative Group. Empagliflozin in CKD. NEJM. 2023
• Bakris GL et al. FIDELIO-DKD: Finerenone in Diabetic Kidney Disease. NEJM. 2020
• Perkovic V et al. FLOW: Semaglutide in CKD with T2DM. NEJM. 2024
• Inker LA et al. New Creatinine- and Cystatin C-Based Equations (CKD-EPI 2021). NEJM. 2021
• SHARP Collaborative Group. Effects of Lowering LDL Cholesterol in CKD. Lancet. 2011

Read this lecture as Markdown